This discordance in gene or protein expression between primary and recurrent BC is link to estrogen receptor (ER), progesterone receptor (PgR) and the oncogenic human epidermal growth factor receptor 2 (HER2) and may include other potential drug targets. This evidence concerns the gene ESR1 and breast cancer.